| Autor: |
Fuchs M; Michael Fuchs, MD and Helen Goergen, Dipl-Math, German Hodgkin Study Group, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany; Carsten Kobe, MD, Department of Nuclear Medicine, University of Cologne, Cologne, Germany; and Peter Borchmann, MD, PhD and Andreas Engert, MD, German Hodgkin Study Group, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany., Goergen H; Michael Fuchs, MD and Helen Goergen, Dipl-Math, German Hodgkin Study Group, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany; Carsten Kobe, MD, Department of Nuclear Medicine, University of Cologne, Cologne, Germany; and Peter Borchmann, MD, PhD and Andreas Engert, MD, German Hodgkin Study Group, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany., Kobe C; Michael Fuchs, MD and Helen Goergen, Dipl-Math, German Hodgkin Study Group, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany; Carsten Kobe, MD, Department of Nuclear Medicine, University of Cologne, Cologne, Germany; and Peter Borchmann, MD, PhD and Andreas Engert, MD, German Hodgkin Study Group, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany., Borchmann P; Michael Fuchs, MD and Helen Goergen, Dipl-Math, German Hodgkin Study Group, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany; Carsten Kobe, MD, Department of Nuclear Medicine, University of Cologne, Cologne, Germany; and Peter Borchmann, MD, PhD and Andreas Engert, MD, German Hodgkin Study Group, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany., Engert A; Michael Fuchs, MD and Helen Goergen, Dipl-Math, German Hodgkin Study Group, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany; Carsten Kobe, MD, Department of Nuclear Medicine, University of Cologne, Cologne, Germany; and Peter Borchmann, MD, PhD and Andreas Engert, MD, German Hodgkin Study Group, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany. |
